XML 106 R61.htm IDEA: XBRL DOCUMENT v3.23.1
COLLABORATION ARRANGEMENTS (Details)
 1 Months Ended 12 Months Ended
Mar. 31, 2022
USD ($)
Apr. 30, 2019
item
Dec. 31, 2018
USD ($)
Dec. 31, 2018
CNY (¥)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2021
CNY (¥)
Dec. 31, 2020
USD ($)
Dec. 31, 2020
CNY (¥)
Dec. 31, 2019
CNY (¥)
Aug. 31, 2022
USD ($)
Apr. 30, 2022
USD ($)
Feb. 28, 2021
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative                          
Revenues         $ 9,292,724 $ 10,175,258   $ 700,913          
Accounts receivable, net           3,000,000              
Guilin Sanjin Pharmaceutical Co., Ltd. License Agreement                          
Collaborative Arrangement and Arrangement Other than Collaborative                          
Upfront cash payment received     $ 1,511,168 ¥ 10,000,000                  
Agreed period for not to grant rights associated with antibodies to third parties     3 years 3 years                  
Dragon Boat Biopharmaceutical (Shanghai) Limited License Agreement                          
Collaborative Arrangement and Arrangement Other than Collaborative                          
Upfront cash payment received               573,378 ¥ 4,000,000        
Agreed period for not to grant rights associated with antibodies to third parties         3 years                
Revenues         $ 0 1,240,022 ¥ 8,000,000   ¥ 0 ¥ 0      
Milestone fee received           620,011 ¥ 4,000,000            
ADCT Collaboration Agreement                          
Collaborative Arrangement and Arrangement Other than Collaborative                          
Revenues           225,000   225,000          
Maximum number of selected targets, agreed for generation of antibodies | item   2                      
Minimum threshold written notice period for termination of agreement         30 days                
Period for reservation of target right         1 year                
Other income               $ 100,000          
Exelixis Inc Agreement                          
Collaborative Arrangement and Arrangement Other than Collaborative                          
Upfront cash payment received         $ 1,100,000 11,000,000              
Revenues         0 8,500,000              
Payment of upfront-refundable fee                       $ 1,100,000 $ 11,000,000
Milestone payments receivable based on development and regulatory milestones                         127,500,000
Milestone payments receivable based on sales                         $ 262,500,000
Accounts receivable, net           $ 3,000,000              
ADCT Material Transfer and Option Agreement                          
Collaborative Arrangement and Arrangement Other than Collaborative                          
Revenues         300,000                
Payment of upfront-refundable fee                     $ 300,000    
Sanofi Agreement                          
Collaborative Arrangement and Arrangement Other than Collaborative                          
Upfront cash payment received $ 17,500,000       17,500,000                
Revenues         $ 8,992,724                
Milestone payments receivable based on development and regulatory milestones 173,500,000                        
Milestone payments receivable based on sales $ 450,000,000